Tag: 5-ala
-
5-ALA available in Wales by April
The Cardiff and Vale University Health Board are planning to start using 5-ALA (5-Amino-Levulinic Acid) for eligible brain tumour patients by the end of the financial year
-
Our research update into glioblastoma, adaptive trials, and the ‘pink drink’
Our Research Engagement Manager Becky Birch, outlines developments highlighted by Tessa Jowell’s debate
-
5-ALA gets FDA approval
The United States’ Food and Drug Administration (FDA) has approved the use of aminolevulinic acid hydrochloride as an optical imaging agent for use in people affected by high grade gliomas.
-
Brain tumour patients denied life-extending drug in ‘postcode lottery’
A drug that can extend the lives of brain tumour patients is being withheld by some NHS Trusts on the grounds of cost.
-
First stage of Addenbrooke’s trials of glioblastoma ‘pink drink’ research nears completion
Dr Colin Watts’ research, funded by us, uses fluorescent dye to reveal different parts of glioblastoma tumours during surgery.